




SC+

Haemodialysis System

More time living

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in a range of care settings. SC+ is designed with you in mind and provides flexibility for patients, carers and providers



Our mission at Quanta is to improve the lives of patients by using innovative design and cutting edge technology to provide affordable solutions in renal care

End Stage Renal Disease and Haemodialysis

Lifestyle, diet and ageing populations are negatively impacting renal health, with end stage renal disease affecting millions of patients worldwide. Haemodialysis is a lifesaving treatment delivered to over two million people globally

A number of studies have shown that 30-40% of patients are capable of self-dialysis, and that regular dialysis improves patient outcomes and quality of life¹

A major factor limiting growth of self-care and home haemodialysis is the lack of easy to use, flexible and cost effective dialysis systems. SC+ addresses these issues, giving patients the best opportunity to take greater control of their treatment

SC+
Haemodialysis System

Easy to use

- Simple to load single-use disposable cartridges
- Intuitive design and functionality
- Straightforward on-screen messages for easy set-up and operation
- No need to disinfect between each treatment



Design

SC+ is designed with you in mind. Whether you're a patient, provider or practitioner, SC+ provides solutions through innovative design



Performance

SC+ provides next generation solutions in renal care without compromising on performance



Choice

SC+ is designed to provide flexibility across a range of care settings and treatment programmes. SC+ delivers consistent performance throughout the journey²



Cost-effectiveness

In order to truly improve the lives of patients and carers, innovation must be affordable and accessible. As well as clinical benefits,^{2,3} SC+ also delivers a range of economic benefits^{5,6,7} through forward thinking design and technology



Health Economics


As the number of patients requiring renal replacement therapy steadily increases, it's important to identify treatments that are both clinically beneficial and cost-effective

The reduced direct cost of home or self-care haemodialysis is influenced by savings in nursing resource and hospital transport. SC+ also reduces the cost burden to healthcare providers and alleviates in-centre capacity constraints

Market Potential

Quanta's unique approach to dialysis addresses a large and rapidly growing global dialysis [products] market worth a total of \$73bn currently⁸

- 2.8 million dialysis patients worldwide in 2015⁸
- Estimated to grow to c. four million by 2020
- 24,166 patients in the UK alone, in 2015⁹



References

1. Ledebro, I; Ronco, C; NDT Plus (2008) 6: 403–408. The best dialysis therapy? Results from an international survey among nephrology professionals
2. SC-00879-Rev A
3. SC-00879-Rev A
4. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998;13 (suppl 6):S10-4
5. SC-01099-Rev A
6. SC-01098-Rev A
7. SC-01098-Rev A
8. Fresenius Annual Report 2015
9. 18th Annual Report, UK Renal Registry

Who we are

Founded in 2008. Privately owned and based in Alcester, UK

Investors

- Air Liquide
- b-to-v Partners AG
- IMI
- Kuwait Life Sciences Company
- NBGI Ventures
- Seroba Kernal LifeSciences
- Seventure Partners
- Wellington Partners

Management

John E. Milad
Chief Executive Officer

Willem Baralt
Chief Financial Officer

Peter Hoyer
Chief Commercial Officer

Prof. Clive Buckberry
Chief Technology Officer



+44 (0) 1789 400043
enquiries@quantafs.com
www.quantafs.com

Quanta Dialysis Technologies
Tything Road, Alcester,
Warwickshire, B49 6EU
United Kingdom

